Evidence map›Paper›PMID 31918721›Full record

ArticleJournal of nanobiotechnology2020

Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer.

Gaofeng Liang, Yanliang Zhu, Doulathunnisa Jaffar Ali, Tian Tian, Huantian Xu, Ke Si, Bo Sun, Baoan Chen, Zhongdang Xiao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 392 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
392citing papers in PubMed, 1 pooled it
33.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

392 citing papers in PubMed, 1 synthesis or guideline pooled it, 671 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

332 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Gaofeng LiangDepartment of Hematology, Zhongda Hospital, Medical School of Southeast University, Nanjing, 210009, China.
Yanliang ZhuDepartment of Hematology, Zhongda Hospital, Medical School of Southeast University, Nanjing, 210009, China.
Doulathunnisa Jaffar AliState Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, Jiangsu, China.
Tian TianDepartment of Neurobiology, Key Laboratory of Human Functional Genomics of Jiangsu, Nanjing Medical University, Nanjing, 211166, Jiangsu, China.
Huantian XuState Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, Jiangsu, China.
Ke SiState Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, Jiangsu, China.
Bo SunState Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, Jiangsu, China.
Baoan ChenMedical College, Henan University of Science and Technology, Luoyang, 471023, Henan, China. cba8888@hotmail.com.
Zhongdang XiaoState Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, Jiangsu, China. zdxiao@seu.edu.cn.
Southeast University · CNState Key Laboratory of Digital Medical EngineeringHenan University of Science and Technology · CNNanjing Medical University · CNZhongda Hospital Southeast University · CN

Funding

Chinese National Postdoctoral Science Foundation 2017M611661National Natural Science Foundation of China 81671807National Natural Science Foundation of China 81741147
6 · The paper itself

Abstract

background5-Fluorouracil (5-FU) has been commonly prescribed for patients with colorectal cancer (CRC), but resistance to 5-FU is one of the main reasons for failure in CRC. Recently, microRNAs (miRNAs) have been established as a means of reversing the dilemma by regulating signaling pathways involved in initiation and progression of CRC. However, how to safely and effectively deliver miRNA to target cells becomes a main challenge.

resultsIn this study, Engineered exosomes were exploited to simultaneously deliver an anticancer drug 5-FU and miR-21 inhibitor oligonucleotide (miR-21i) to Her2 expressing cancer cells. Purified engineered exosomes from the donor cells loaded with 5-FU and miR-21i via electroporation to introduce into 5-FU-resistant colorectal cancer cell line HCT-116

conclusionThe strategy for co-delivering the functional small RNA and anticancer drug by exosomes foreshadows a potential approach to reverse the drug resistance in CRC and thus to enhance the efficacy of the cancer treatment.

Indexed as

Drug Delivery SystemsDrug Resistance, NeoplasmAnimalsAntineoplastic AgentsColonic NeoplasmsDrug CarriersExosomesFluorouracilHCT116 CellsHumansMice, NudeMicroRNAsNanoparticlesRecombinant Fusion ProteinsTissue DistributionAntineoplastic AgentsDrug CarriersFluorouracilMicroRNAsMIRN21 microRNA, humanRecombinant Fusion Proteins5-FUDelivery systemDrug resistanceExosomesmiR-21 inhibitor

Identifiers

PMID31918721
PMCPMC6950820
OpenAlexW2999495440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.